163 related articles for article (PubMed ID: 36929633)
1. MYH10 Combines with MYH9 to Recruit USP45 by Deubiquitinating Snail and Promotes Serous Ovarian Cancer Carcinogenesis, Progression, and Cisplatin Resistance.
Liu L; Chen C; Liu P; Li J; Pang Z; Zhu J; Lin Z; Zhou H; Xie Y; Lan T; Chen ZS; Zeng Z; Fang W
Adv Sci (Weinh); 2023 May; 10(14):e2203423. PubMed ID: 36929633
[TBL] [Abstract][Full Text] [Related]
2. miR-6089/MYH9/β-catenin/c-Jun negative feedback loop inhibits ovarian cancer carcinogenesis and progression.
Liu L; Ning Y; Yi J; Yuan J; Fang W; Lin Z; Zeng Z
Biomed Pharmacother; 2020 May; 125():109865. PubMed ID: 32058212
[TBL] [Abstract][Full Text] [Related]
3. Nonmuscle myosin II isoforms interact with sodium channel alpha subunits.
Dash B; Han C; Waxman SG; Dib-Hajj SD
Mol Pain; 2018; 14():1744806918788638. PubMed ID: 29956586
[TBL] [Abstract][Full Text] [Related]
4. ACTN1 promotes HNSCC tumorigenesis and cisplatin resistance by enhancing MYH9-dependent degradation of GSK-3β and integrin β1-mediated phosphorylation of FAK.
Cui L; Lu Y; Zheng J; Guo B; Zhao X
J Exp Clin Cancer Res; 2023 Dec; 42(1):335. PubMed ID: 38057867
[TBL] [Abstract][Full Text] [Related]
5. MYH9 is a novel cancer stem cell marker and prognostic indicator in esophageal cancer that promotes oncogenesis through the PI3K/AKT/mTOR axis.
Kai JD; Cheng LH; Li BF; Kang K; Xiong F; Fu JC; Wang S
Cell Biol Int; 2022 Dec; 46(12):2085-2094. PubMed ID: 36030536
[TBL] [Abstract][Full Text] [Related]
6. Input-specific regulation of hippocampal circuit maturation by non-muscle myosin IIB.
Ozkan ED; Aceti M; Creson TK; Rojas CS; Hubbs CR; McGuire MN; Kakad PP; Miller CA; Rumbaugh G
J Neurochem; 2015 Aug; 134(3):429-44. PubMed ID: 25931194
[TBL] [Abstract][Full Text] [Related]
7. Myosin Heavy Chain 10 (MYH10) Gene Silencing Reduces Cell Migration and Invasion in the Glioma Cell Lines U251, T98G, and SHG44 by Inhibiting the Wnt/β-Catenin Pathway.
Wang Y; Yang Q; Cheng Y; Gao M; Kuang L; Wang C
Med Sci Monit; 2018 Dec; 24():9110-9119. PubMed ID: 30552850
[TBL] [Abstract][Full Text] [Related]
8. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9.
Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of MYH10 driven by chromosome 17p13.1 deletion promotes hepatocellular carcinoma metastasis through activation of the EGFR pathway.
Jin Q; Cheng M; Xia X; Han Y; Zhang J; Cao P; Zhou G
J Cell Mol Med; 2021 Dec; 25(24):11142-11156. PubMed ID: 34738311
[TBL] [Abstract][Full Text] [Related]
10. GRHL2 Upregulation Predicts a Poor Prognosis and Promotes the Resistance of Serous Ovarian Cancer to Cisplatin.
Nie Y; Ding Y; Yang M
Onco Targets Ther; 2020; 13():6303-6314. PubMed ID: 32636649
[TBL] [Abstract][Full Text] [Related]
11. Cinobufotalin powerfully reversed EBV-miR-BART22-induced cisplatin resistance via stimulating MAP2K4 to antagonize non-muscle myosin heavy chain IIA/glycogen synthase 3β/β-catenin signaling pathway.
Liu Y; Jiang Q; Liu X; Lin X; Tang Z; Liu C; Zhou J; Zhao M; Li X; Cheng Z; Li L; Xie Y; Liu Z; Fang W
EBioMedicine; 2019 Oct; 48():386-404. PubMed ID: 31594754
[TBL] [Abstract][Full Text] [Related]
12. Long Non-coding RNA
Yim GW; Kim HJ; Kim LK; Kim SW; Kim S; Nam EJ; Kim YT
Cancer Res Treat; 2017 Jul; 49(3):656-668. PubMed ID: 27737536
[TBL] [Abstract][Full Text] [Related]
13. DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Yamaguchi N; Mimoto R; Yanaihara N; Imawari Y; Hirooka S; Okamoto A; Yoshida K
Tumour Biol; 2015 Aug; 36(8):5913-23. PubMed ID: 25712377
[TBL] [Abstract][Full Text] [Related]
14. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis.
Yang M; Xie X; Ding Y
Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA (LncRNA) MRPL23-AS1 promotes tumor progression and carcinogenesis in osteosarcoma by activating Wnt/β-catenin signaling via inhibiting microRNA miR-30b and upregulating myosin heavy chain 9 (MYH9).
Zhang H; Liu S; Tang L; Ge J; Lu X
Bioengineered; 2021 Dec; 12(1):162-171. PubMed ID: 33356805
[TBL] [Abstract][Full Text] [Related]
16. Myosin heavy chain 10 (MYH10) is required for centriole migration during the biogenesis of primary cilia.
Hong H; Kim J; Kim J
Biochem Biophys Res Commun; 2015 May; 461(1):180-5. PubMed ID: 25881509
[TBL] [Abstract][Full Text] [Related]
17. MUS81 is associated with cell proliferation and cisplatin sensitivity in serous ovarian cancer.
Xie S; Zheng H; Wen X; Sun J; Wang Y; Gao X; Guo L; Lu R
Biochem Biophys Res Commun; 2016 Aug; 476(4):493-500. PubMed ID: 27255997
[TBL] [Abstract][Full Text] [Related]
18. LncRNA LIFR-AS1 overexpression suppressed the progression of serous ovarian carcinoma.
Liu F; Cao L; Zhang Y; Xia X; Ji Y
J Clin Lab Anal; 2022 Aug; 36(8):e25470. PubMed ID: 35778954
[TBL] [Abstract][Full Text] [Related]
19. Nonmuscle myosin II-B (myh10) expression analysis during zebrafish embryonic development.
Huang Y; Wang X; Wang X; Xu M; Liu M; Liu D
Gene Expr Patterns; 2013 Oct; 13(7):265-70. PubMed ID: 23665442
[TBL] [Abstract][Full Text] [Related]
20. CircSETDB1 knockdown inhibits the malignant progression of serous ovarian cancer through miR-129-3p-dependent regulation of MAP3K3.
Li B; Zhang L
J Ovarian Res; 2021 Nov; 14(1):160. PubMed ID: 34789310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
